Old Web
English
Sign In
Acemap
>
authorDetail
>
Gabor Kari
Gabor Kari
Pathology
Medicine
Synovial sarcoma
NY-ESO-1
open label
6
Papers
179
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043).
2017
Journal of Clinical Oncology
Crystal L. Mackall
William D. Tap
John Glod
Mihaela Druta
Warren Chow
Dejka M. Araujo
Stephan A. Grupp
Brian A. Van Tine
Karen Chagin
Erin Van Winkle
Gabor Kari
Trupti Trivedi
Elliot Norry
Tom Holdich
Arundathy N. Bartlett-Pandite
Rafael G. Amado
Sandra P. DAngelo
Show All
Source
Cite
Save
Citations (16)
A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).
2017
Journal of Clinical Oncology
Kunle Odunsi
Mihaela C. Cristea
Oliver Dorigo
Amir A. Jazaeri
Brian M. Slomovitz
Karen Chagin
Erin Van Winkle
Gabor Kari
Malini Iyengar
Elliot Norry
Arundathy N. Bartlett-Pandite
Rafael G. Amado
Show All
Source
Cite
Save
Citations (3)
Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR.
2016
Journal of Clinical Oncology
Crystal L. Mackall
Sandra P. DAngelo
Mihaela C. Cristea
Kunle Odunsi
Elliot Norry
Lini Pandite
Tom Holdich
Gabor Kari
Indu Ramachandran
Lilliam Ribeiro
Gwendolyn Binder-Scholl
Rafael G. Amado
Show All
Source
Cite
Save
Citations (5)
1